Deoxyribonucleic acid triplex formation inhibits granulocyte macrophage colony-stimulating factor gene expression and suppresses growth in juvenile myelomonocytic leukemic cells

Journal of Clinical Investigation

Volumn 99, Issue 12, 1997, Pages 3000-3008

  Kochetkova, Marina ^a   Iversen, Per O ^a   Lopez, Angel F ^a   Shannon, M Frances ^a,b  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b HANSON INSTITUTE   (Australia)

Author keywords

Gene expression; Malignancy; Nuclear factor B Rel; Oligonucleotides; Proliferation; Tumor necrosis factor

Indexed keywords

DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BONE MARROW CELL; CASE REPORT; CELL VIABILITY; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

EID: 0030925139     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119495     Document Type: Article

References (41)

1. Gasson, J.C. 1991. Molecular physiology of granulocyte-macrophage colony stimulating factor. Blood. 77:1131-1145.
2. Russell, N.H. 1992. Autocrine growth factors and leukaemic haemopoesis. Blood Rev. 6:149-156.
3. Young, D.C., K. Wagner, and J.D. Griffin. 1987. Constitutive expression of the granulocyte-macrophage colony stimulating factor gene in acute myeloblastic leukemia. J. Clin. Invest. 79:100-106.
4. Xu, W., G.S. Firestein, R. Taetle, K. Kaushansky, and N.J. Zvafler. 1989. Cytokines in chronic inflammatory arthritis. II. GM-CSF in rheumatouid synovial effusions. J. Clin. Invest. 83:876-882.
5. Castro-Malaspina, H., G. Schaison, S. Passe, A. Pasquier, R. Berger, C. Bayle-Weisgerber, D. Miller, M. Seligmann, and J. Bernard. 1984. Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Cancer. 54: 675-686.
6. Castleberry, R.P., P.D. Emanuel, K.S. Zuckerman, S. Cohn, L. Strauss, R.L. Byrd, A. Homans, S. Chaffee, R. Nitschke, and R.J. Gualtieri. 1994. A pilot study of isoretinoin in the treatment of juvenile chronic myelogenous leukemia. N. Engl. J. Med. 331:1680-1684.
7. Chan, H.S.L., Z. Estrov, S.S. Weitzman, and M.H. Freedman. 1987. The value of intensive combination chemotherapy for juvenile chronic myelogeneous leukemia. J. Clin. Oncol. 5:1960-1967.
8. Sanders, J.E., CD. Buckner, E.D. Thomas, R. Fleischer, K.M. Sullivan, F.A. Appelbaum, and R. Storb. 1988. Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. Blood. 71:1144-1146.
9. Emanuel, P.D., L.J. Bates, S.-W. Zhu, R.P. Castleberry, R.J. Gualtieri, and K.S. Zuckerman. 1991. The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. Exp. Hematol. (Charlottesv). 19:1017-1024.
10. Emanuel, P.D., L.J. Bates, R.P. Castleberry, R.J. Gualtieri, and K.S. Zuckerman. 1991. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 77:925-929.
11. Gualtieri, R.J., P.D. Emanuel, K.S. Zuckerman, G. Martin, S.C. Clark, R.K. Shadduck, R.A. Dracker, J. Akabutu, R. Nitschke, M.L. Hetherington, et al. 1989. Granulocyte-macrophage colony-stimulating factor is an endogeneous regulator of cell proliferation in juvenile chronic myelogenous leukemia. Blood. 74:2360-2367.
12. Freedman, M.H., A. Cohen, T. Grunberger, N. Bunin, R.E. Luddy. E.F. Saunders, N. Shahidi, A. Lau, and Z. Estrov. 1992. Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogeneous leukaemia. Br. J. Haematol. 80:40-48.
13. Iversen, P.O., R.L. Rodwell, L. Pitcher, K.M. Taylor, and A.F. Lopez. 1996. Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulating factor analogue E21R. Blood. 80:479-486.
14. Stull, R.A., and F.C. Szoka. 1995. Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. Pharm. Res. (NY). 12:465-483.
15. Helene, C., N.T. Thuong, and A. Harrel-Bellan. 1992. Control of gene expression by triple helix-forming oligonucleotides. The antigene strategy. Ann. NY Acad. Sci. 660:27-36.
16. Moser, H.E., and P.B. Dervan. 1987. Sequence-specific cleavage of double helical DNA by triple helix formation. Science (Wash. DC). 238:645-650.
17. Beal, P.A., and P.B. Dervan. 1991. Second structural motif for recognition of DNA by oligonucleotide-directed triple helix formation. Science (Wash. DC). 251:1360-1363.
18. Cooney, M., C. Chernuszewicz, E.H. Postel, S.J. Flint, and M.E. Hogan. 1988. Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science (Wash DC). 241:456-459.
19. Grigoriev, M., D. Praseuth, A.L. Guieysse. P. Robin, N.T. Thuong, C. Helene, and A. Harrel-Bellan. 1993. Inhibition of gene expression by triple helix-directed DNA cross-linking at specific sites. Proc. Natl. Acad. Sci. USA. 90: 3501-3505.
20. Ing, N.H., J.M. Beekman, D.J. Kessler, M. Murphy, K. Jayaraman, J.G. Zendegui. M.E. Hogan, B.W. O'Malley, and M.-J. Tsai. 1993. In vivo transcription of a progesterone-responsive gene is inhibited by a triplex forming oligonucleotide. Nucleic Acids Res. 21:2789-2796.
21. Kochetkova, M., and M.F. Shannon. 1996. DNA triplex formation selectively inhibits granulocyte-macrophage colony-stimulating factor gene expression in human T cells. J. Biol. Chem. 271:14438-14444.
22. Jenkins, F., P.N. Cockerill, D. Bohmann, and M.F. Shannon. 1995. Multiple signals are required for function of the human GM-CSF gene promoter in T cells. J. Immunol. 155:1240-1251.
23. Himes, S.R., L.S.Coles, R. Katsikeros, R.K.Lang, and M.F. Shannon. 1993. HTLV-1 tax activation of the GM-CSF and G-CSF promoters requires the interaction of NF-KB with other transcription factor families. Oncogene. 8: 3189-3197.
24. Shannon, M.F., S.R. Himes, and L.S. Coles. 1995. GM-CSF and IL-2 share common control mechanisms in response to costimulatory signals in T-cells. J. Leukocyte Biol. 57:1-7.
25. Cockerill, P.N., M.F. Shannon, A.C. Bert, G.R. Ryan, and M.A.Vadas. 1993. The GM-CSF/IL-3 locus is regulated by an inducible cyclosporin A-sensitivc enhancer. Proc. Natl. Acad. Sci. USA. 90:2466-2470.
26. Miyamoto, S., and I.M. Verma. 1995. Rel/NF-κB/IκB story. Adv. Cancer Res. 46:255-292.
27. Siebenlist, U., G. Franzoso, and K. Brown. 1994. Structure, regulation and function of NF-κB. Annu. Rev. Cell Biol. 10:405-455.
28. Brown, C.Y., K.A. Lagnado, M.A. Vadas, and G.Y. Goodall. 1996. Differential regulation of the stability of cytokine mRNAs in lipopolysaccharide-activated blood monocytes in response to interleukin-10 J. Biol. Chem. 271: 20108-20112.
29. + cells in to myeloid lineage. Blood. 80:1405-1412.
30. Grumont, R.J., and S. Gerondakis. 1994. The subunit composition of NF-κB complexes changes during B-cell development. Cell Growth Differ. 5: 1321-1331.
31. Schreiber, E., P. Matthias, M.M. Muller, and W. Schaffner. 1989. Rapid detection of octamer binding proteins with 'mini extracts', prepared from a small number of cells. Nucleic Acids Res. 17:6419.
32. Wu, H., and G. Lozano. 1994. NF-κB activation of p53. J. Biol. Chem. 269:20067-20074.
33. Lang, R.A., D. Metcalf, R.A. Cuthbertson, I. Lyons, E. Stanley, A. Kelso, G. Kannourakis, D-J. Williamson, G.K. Klintworth, T.J. Gonda, and A.R. Dunn. 1987. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell. 51:675-686.
34. Dokter, W.H., L. Tuyt, S.J. Sierdsema, MT. Esselink, and E. Vellenga. 1995. The spontaneous expression of IL-1β and IL-6 is associated with spontaneous expression of AP-1 and NF-κB transcription factor in acute myeloblastic leukemia cells. Leukemia (Baltimore). 9:425-432.
35. Gerondakis, S., A. Strasser, D. Metcalf, G. Grigoriadis, J.-P.Y. Schreelinck, and R.J. Grumont. 1996. Rel-deficient T cells exibit defects in the production of IL-3 and GM-CSF. Proc. Natl. Acad. Sci. USA. 93:3405-3409.
36. Himes, S.R., R. Katsikeros, and M.F. Shannon. 1996. Costimulation of cytokine gene expression in T cells by the HTLV-1 trans-activator Tax. J. Virol 70:4001-4008.
37. Drouet, C., A.N. Shakhov, and C.V. Jongeneel. 1991. Enhancers and transcription factors controlling the inducibility of the TNFα promoter in primary macrophages. J. Immunol. 147:1694-1700.
38. Mirabelli, C.K., C.F. Bennett, K. Anderson, and S.T. Crooke. 1991. In vitro and in vivo pharmacologic activities of antisense oligonucleotides. AntiCancer Drug Des. 6:647-661.
39. Maher, L.J., III. 1996. Prospects for the therapeutic use of antigene oligonucleotides. Cancer Invest. 14:66-82.
40. Dugunes, N., and P.L. Felgner. 1993. Intracellular delivery of nucleic acids and transcription factors by cationic liposomes. Methods Enzymol. 221:303-306.
41. Guy-Caffey, K.J., V. Bodepudi, S.J. Bishop, K. Jayaraman, and N. Chaudhary. 1995. Novel polyaminolipids enhance the cellular uptake of oligonucleotides. J. Biol. Chem. 270:31391-31396.